Alamar Biosciences, Inc. is a leading proteomics company that empowers researchers to explore the proteome with unprecedented precision and depth. Utilizing cutting-edge NULISA technology, Alamar provides highly sensitive and dynamic solutions for detecting protein biomarkers in liquid biopsy specimens. Their mission is to advance precision proteomics and enable the earliest detection of diseases, facilitating personalized medicine and earlier disease diagnosis. Collaborating with institutions like The Michael J. Fox Foundation, Alamar Biosciences focuses on developing and validating biomarkers for Alzheimer's, Parkinson's, and other diseases. With a commercial presence in the APAC region, the company supports translational scientists in their biomarker discovery and validation journeys with innovative and automated workflows such as the ARGO HT System.